Rosiglitazone in Canada: experience in clinical practice

Beata Patasi Assistant Professor, Faculty of Medicine University of Ottawa, CMM- Division of Clinical and Functional Anatomy, 451 Smyth Rd, office # 2162, Ottawa, ON, K1H 8M5, Canada, USA +1 613 562 5800 ext. 8702; +1 613 562 5687; [email protected]; Research Coordinator, Canadian Centre for Research on Diabetes, Diabetes Clinic, 218 Percy St., Smiths Falls, ON K7A 4W8, Canada, USA

, MD RDMS LMCC,

Deborah MacNair Clinical Nurse and Diabetes Educator, Canadian Centre for Research on Diabetes, Diabetes Clinic, 218 Percy St., Smiths Falls, ON K7A 4W8, Canada, USA +1 613 284 0145; +1 613 283 9020; [email protected]

, RN BSN,

Ryan J Marble Medical Student (University of Toronto), Diabetes Clinic, Canadian Centre for Research on Diabetes218 Percy St., Smiths Falls, ON K7A 4W8, Canada +1 613 284 0145; +1 613 283 9020; [email protected]

, Bsc &

J Robin Conway Medical Director, Canadian Centre for Research on Diabetes, Diabetes Clinic, 218 Percy St., Smiths Falls, ON K7A 4W8, Canada, USA +1 613 284 0145; +1 613 283 9020; [email protected]

, MD

Abstract

Background: Type 2 diabetes mellitus is a growing public health concern throughout the world. In North America, most people with type 2 diabetes receive care for their diabetes from a general or family practitioner and so the performance of a new therapeutic agent is best assessed in this setting. The first of a novel new family of oral hypoglycemic agents, rosiglitazone became available in Canada in February 2000. Objective and methods: In this article, we discuss an observational, prospective, cohort, open-label study to assess the clinical efficacy and safety of rosiglitazone in a typical type 2 diabetes population receiving care at a family practice setting with several drug therapies and comorbidities. Results/conclusion: During seven and a half years of experience in our clinical practice, rosiglitazone has been shown as a safe and effective treatment for type 2 diabetics on maximal tolerated or therapeutic doses of metformin and sulfonylurea, in a family practice setting.

Keywords::

Notes

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Rosiglitazone in Canada: experience in clinical practice

Information for

Open access

Opportunities

Help and information

Rosiglitazone in Canada: experience in clinical practice

Abstract

Notes

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature